Organization
Department of Neurosurgery and Neuro-Oncology, National Cancer Center Research Institute, Tokyo, Japan
4 abstracts
Abstract
Phase I clinical trial of 64Cu-ATSM for malignant brain tumors.Org: Department of Diagnostic and Interventional Radiology, Kanagawa Cancer Center Hospital, Yokohama, Japan, Department of Neurosurgery and Neuro-Oncology, National Cancer Center Research Institute, Tokyo, Japan, Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan, Department of Neurosurgery, Kanagawa Cancer Center Hospital, Yokohama, Japan, Department of Neurosurgery and Neuro-Oncology, Tokyo, Japan,
Abstract
Ombipepimut dosing emulsion (ODE) + bevacizumab (bev) vs bev alone in patients (pts) with recurrent or progressive glioblastoma (rGBM).Org: John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Hackensack University Medical Center, Severance Hospital, Department of Neurosurgery and Neuro-Oncology, National Cancer Center Research Institute, Tokyo, Japan, National Cancer Center Research Institute,
Abstract
Final three-year follow-up analysis of phase I/II study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma.Org: Department of Neurosurgery, Peking Union Medical College Hospital, Beijing, China, Osaka International Cancer Institute, Osaka, Japan, Department of Neurosurgery and Neuro-Oncology, National Cancer Center Research Institute, Tokyo, Japan, National Cancer Center Hospital East, Kashiwa, Japan, Kyorin University Faculty of Medicine,
Abstract
Feasibility and utility of the custom RNA-seq for the identification of therapeutic targets and diagnostic biomarkers in glioma.Org: Department of Neurosurgery and Neuro-Oncology, National Cancer Center Research Institute, Tokyo, Japan, National Cancer Center Hospital East, Kashiwa, Japan, Division of Cellular Signaling, National Cancer Center Research Institute, Department of Brain Disease Translational Research,